Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG CLASS:

ERK1 inhibitor

DRUG CLASS:

ERK1 inhibitor

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Related drugs:

BRAF L597Q	Solid Tumor	BRAF L597Q	Solid Tumor	BVD-523 Sensitive: B - Late Trials BVD-523 Sensitive : B	BVD-523 Sensitive: B - Late Trials BVD-523 Sensitive : B
BRAF G469A	Solid Tumor	BRAF G469A	Solid Tumor	BVD-523 Sensitive: B - Late Trials BVD-523 Sensitive : B	BVD-523 Sensitive: B - Late Trials BVD-523 Sensitive : B
BRAF G469V	Solid Tumor	BRAF G469V	Solid Tumor	BVD-523 Sensitive: B - Late Trials BVD-523 Sensitive : B	BVD-523 Sensitive: B - Late Trials BVD-523 Sensitive : B
BRAF L485W	Solid Tumor	BRAF L485W	Solid Tumor	BVD-523 Sensitive: B - Late Trials BVD-523 Sensitive : B	BVD-523 Sensitive: B - Late Trials BVD-523 Sensitive : B
BRAF V600E	Melanoma	BRAF V600E	Melanoma	JSI-1187 Sensitive: C2 – Inclusion Criteria JSI-1187 Sensitive : C2	JSI-1187 Sensitive: C2 – Inclusion Criteria JSI-1187 Sensitive : C2
NRAS mutation	Melanoma	NRAS mutation	Melanoma	BVD-523 Sensitive: C2 – Inclusion Criteria BVD-523 Sensitive : C2	BVD-523 Sensitive: C2 – Inclusion Criteria BVD-523 Sensitive : C2
BRAF V600E	Colorectal Cancer	BRAF V600E	Colorectal Cancer	LY3214996 Sensitive: C2 – Inclusion Criteria LY3214996 Sensitive : C2	LY3214996 Sensitive: C2 – Inclusion Criteria LY3214996 Sensitive : C2
BRAF mutation	Melanoma	BRAF mutation	Melanoma	BVD-523 Sensitive: C2 – Inclusion Criteria BVD-523 Sensitive : C2	BVD-523 Sensitive: C2 – Inclusion Criteria BVD-523 Sensitive : C2
KRAS mutation	Colorectal Cancer	KRAS mutation	Colorectal Cancer	ERAS-007 Sensitive: C2 – Inclusion Criteria ERAS-007 Sensitive : C2	ERAS-007 Sensitive: C2 – Inclusion Criteria ERAS-007 Sensitive : C2
BRAF V600E	Colorectal Cancer	BRAF V600E	Colorectal Cancer	ERAS-007 Sensitive: C2 – Inclusion Criteria ERAS-007 Sensitive : C2	ERAS-007 Sensitive: C2 – Inclusion Criteria ERAS-007 Sensitive : C2
KRAS mutation	Non Small Cell Lung Cancer	KRAS mutation	Non Small Cell Lung Cancer	ERAS-007 + ERAS-601 Sensitive: C2 – Inclusion Criteria ERAS-007 + ERAS-601 Sensitive : C2	ERAS-007 + ERAS-601 Sensitive: C2 – Inclusion Criteria ERAS-007 + ERAS-601 Sensitive : C2
BRAF V600E	Melanoma	BRAF V600E	Melanoma	LY3214996 Sensitive: C2 – Inclusion Criteria LY3214996 Sensitive : C2	LY3214996 Sensitive: C2 – Inclusion Criteria LY3214996 Sensitive : C2